OVERDOSE

In controlled overdosage, daily doses of 360 mg of ketorolac tromethamine IV/IMgiven for five days (3 times the highest recommended dose), caused abdominal pain and peptic ulcers which healed after discontinuation of doses. Metabolic acidosis has been reported following intentional overdosage.

Dialysis does not significantly clear ketorolac tromethamine from the blood stream.

CONTRAINDICATIONS

(see also BOXED WARNING)

	Ketorolac tromethamine is CONTRAINDICATED in patients with active peptic ulcer disease, in patients with recent gastrointestinal bleeding or perforation, and in patients with a history of peptic ulcer disease or gastrointestinal bleeding.
	Ketorolac tromethamine is CONTRAINDICATED in patients with advanced renal impairment, or in patients at risk of renal failure due to volume depletion (see WARNINGS for correction of volume depletion).
	Ketorolac tromethamine is CONTRAINDICATED in labor and delivery because, through its prostaglandin synthesis inhibitory effect, it may adversely affect fetal circulation and inhibit uterine contraindications, thus increasing the risk of uterine hemorrhage.
	The use of ketorolac tromethamine is CONTRAINDICATED in nursing mothers because of the potential adverse effects of prostaglandin-inhibiting drugs on neonates.
	Ketorolac tromethamine is CONTRAINDICATED in patients with previously demonstrated hypersensitivity to ketorolac tromethamine, or allergic manifestations to aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs).
	Ketorolac tromethamine is CONTRAINDICATED as prophylactic analgesic before any major surgery is critical because of the increased risk of bleeding.
	Ketorolac tromethamine inhibits platelet function and is, therefore, CONTRAINDICATED in patients with suspected or confirmed cerebrovascular bleeding, hemorrhagic diathesis, incomplete hemostasis and those at high risk of bleeding (see WARNINGS and PRECAUTIONS).
	Ketorolac tromethamine is CONTRAINDICATED in patients currently receiving ASA or NSAIDs because of the cumulative risks of inducing serious NSAID related adverse events.
	Ketorolac tromethamine IV/IM is CONTRAINDICATED for neuraxial (epidural or intrathecal) administration due to its alcohol content.
	The concomitant use of ketorolac tromethamine and probenecid is CONTRAINDICATED. Ophthalmic Solution: Acular (ketorolac tromethamine) ophthalmic solution is contraindicated in patients while wearing soft contact lenses and in patients with previously demonstrated hypersensitivity to any of the ingredients in the formulation.